Latest Biotechnology News

Page 25 of 57
Biome Australia Limited has reported its first net profit alongside a 41.6% jump in sales revenue, driven by strong domestic growth and expanding international partnerships.
Ada Torres
Ada Torres
27 Aug 2025
Biome Australia Limited reports its first profitable year since 2018, driven by a 41.6% revenue increase and significant international growth.
Ada Torres
Ada Torres
27 Aug 2025
AdAlta Limited reported a reduced net loss of $4.5 million for FY2025 but flagged material uncertainty over its ability to continue as a going concern, with no dividends declared.
Ada Torres
Ada Torres
27 Aug 2025
Microba Life Sciences reported a 30% increase in revenue to $15.7 million for FY25, driven by strong growth in its core microbiome diagnostic products and successful UK market expansion. Despite narrowing its net loss to $14.9 million, the company is focused on scaling diagnostics adoption and achieving break-even in FY26.
Ada Torres
Ada Torres
26 Aug 2025
Starpharma reports a significant 183% jump in FY25 revenue to $4.9 million, alongside a 31% reduction in losses and a solid cash position of $15.4 million. The biotech firm’s progress underscores growing momentum in its dendrimer technology pipeline.
Ada Torres
Ada Torres
26 Aug 2025
Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.
Ada Torres
Ada Torres
26 Aug 2025
Imugene Limited reported a significant 54% reduction in net loss for FY25, driven by cost efficiencies and promising clinical progress in its immuno-oncology pipeline. The company’s lead asset, azer-cel, achieved a 79% response rate in Phase 1b trials and secured FDA Fast Track designation.
Ada Torres
Ada Torres
26 Aug 2025
Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.
Ada Torres
Ada Torres
25 Aug 2025
Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.
Ada Torres
Ada Torres
25 Aug 2025
Noxopharm has successfully completed the third dosing phase of its HERACLES trial for SOF-SKN™, confirming safety and moving forward to the highest dose cohort in this pioneering autoimmune drug study.
Ada Torres
Ada Torres
25 Aug 2025
Neuren Pharmaceuticals has initiated the first US investigational site for its pivotal Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, marking a significant milestone in addressing this rare neurodevelopmental disorder.
Ada Torres
Ada Torres
25 Aug 2025
Cynata Therapeutics has entered a five-year At-the-Market Subscription Agreement with Acuity Capital, enabling access to up to $7.5 million in standby equity capital with full discretion over timing and pricing.
Ada Torres
Ada Torres
22 Aug 2025